Tags

Type your tag names separated by a space and hit enter

The Ocular Hypertension Treatment Study: topical medication delays or prevents primary open-angle glaucoma in African American individuals.
Arch Ophthalmol 2004; 122(6):813-20AO

Abstract

BACKGROUND

The prevalence of glaucoma is higher in African American individuals than in white individuals.

OBJECTIVE

To report the safety and efficacy of topical ocular hypotensive medication in delaying or preventing the onset of primary open-angle glaucoma (POAG) among African American participants in the Ocular Hypertension Treatment Study.

METHODS

Eligibility criteria included age between 40 and 80 years, intraocular pressure between 24 and 32 mm Hg in one eye and between 21 and 32 mm Hg in the other eye, and no evidence of glaucomatous structural or functional damage by standard clinical measures. Participants were randomized to either the observation group or medication group. Of the 1636 participants randomized, 408 were self-identified as African American.

MAIN OUTCOME MEASURE

The primary outcome was the development of reproducible visual field abnormality and/or reproducible optic disc deterioration attributed to POAG.

RESULTS

Among African American participants, 17 (8.4%) of 203 in the medication group developed POAG during the study (median follow-up, 78 months) compared with 33 (16.1%) of 205 participants in the observation group (hazard ratio, 0.50; 95% confidence interval, 0.28-0.90; P =.02).

CONCLUSION

Topical ocular hypotensive therapy is effective in delaying or preventing the onset of POAG in African American individuals who have ocular hypertension.

Authors+Show Affiliations

Department of Ophthalmology, Maryland Center for Eye Care Associates, Baltimore, USA.No affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info available

Pub Type(s)

Clinical Trial
Journal Article
Randomized Controlled Trial
Research Support, Non-U.S. Gov't
Research Support, U.S. Gov't, P.H.S.

Language

eng

PubMed ID

15197055

Citation

Higginbotham, Eve J., et al. "The Ocular Hypertension Treatment Study: Topical Medication Delays or Prevents Primary Open-angle Glaucoma in African American Individuals." Archives of Ophthalmology (Chicago, Ill. : 1960), vol. 122, no. 6, 2004, pp. 813-20.
Higginbotham EJ, Gordon MO, Beiser JA, et al. The Ocular Hypertension Treatment Study: topical medication delays or prevents primary open-angle glaucoma in African American individuals. Arch Ophthalmol. 2004;122(6):813-20.
Higginbotham, E. J., Gordon, M. O., Beiser, J. A., Drake, M. V., Bennett, G. R., Wilson, M. R., & Kass, M. A. (2004). The Ocular Hypertension Treatment Study: topical medication delays or prevents primary open-angle glaucoma in African American individuals. Archives of Ophthalmology (Chicago, Ill. : 1960), 122(6), pp. 813-20.
Higginbotham EJ, et al. The Ocular Hypertension Treatment Study: Topical Medication Delays or Prevents Primary Open-angle Glaucoma in African American Individuals. Arch Ophthalmol. 2004;122(6):813-20. PubMed PMID: 15197055.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - The Ocular Hypertension Treatment Study: topical medication delays or prevents primary open-angle glaucoma in African American individuals. AU - Higginbotham,Eve J, AU - Gordon,Mae O, AU - Beiser,Julia A, AU - Drake,Michael V, AU - Bennett,G Richard, AU - Wilson,M Roy, AU - Kass,Michael A, AU - ,, PY - 2004/6/16/pubmed PY - 2004/7/21/medline PY - 2004/6/16/entrez SP - 813 EP - 20 JF - Archives of ophthalmology (Chicago, Ill. : 1960) JO - Arch. Ophthalmol. VL - 122 IS - 6 N2 - BACKGROUND: The prevalence of glaucoma is higher in African American individuals than in white individuals. OBJECTIVE: To report the safety and efficacy of topical ocular hypotensive medication in delaying or preventing the onset of primary open-angle glaucoma (POAG) among African American participants in the Ocular Hypertension Treatment Study. METHODS: Eligibility criteria included age between 40 and 80 years, intraocular pressure between 24 and 32 mm Hg in one eye and between 21 and 32 mm Hg in the other eye, and no evidence of glaucomatous structural or functional damage by standard clinical measures. Participants were randomized to either the observation group or medication group. Of the 1636 participants randomized, 408 were self-identified as African American. MAIN OUTCOME MEASURE: The primary outcome was the development of reproducible visual field abnormality and/or reproducible optic disc deterioration attributed to POAG. RESULTS: Among African American participants, 17 (8.4%) of 203 in the medication group developed POAG during the study (median follow-up, 78 months) compared with 33 (16.1%) of 205 participants in the observation group (hazard ratio, 0.50; 95% confidence interval, 0.28-0.90; P =.02). CONCLUSION: Topical ocular hypotensive therapy is effective in delaying or preventing the onset of POAG in African American individuals who have ocular hypertension. SN - 0003-9950 UR - https://www.unboundmedicine.com/medline/citation/15197055/full_citation L2 - https://jamanetwork.com/journals/jamaophthalmology/fullarticle/10.1001/archopht.122.6.813 DB - PRIME DP - Unbound Medicine ER -